Kestra Medical Technologies (NASDAQ:KMTS) Insider Traci Umberger Sells 3,580 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTSGet Free Report) insider Traci Umberger sold 3,580 shares of the company’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.04, for a total value of $86,063.20. Following the transaction, the insider directly owned 195,825 shares of the company’s stock, valued at $4,707,633. The trade was a 1.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Stock Up 0.8%

Shares of NASDAQ KMTS opened at $25.27 on Friday. The firm has a fifty day simple moving average of $22.86 and a two-hundred day simple moving average of $22.54. Kestra Medical Technologies, Ltd. has a 12 month low of $14.10 and a 12 month high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $1.48 billion, a PE ratio of -10.44 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTSGet Free Report) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Equities analysts expect that Kestra Medical Technologies, Ltd. will post -2.29 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. The Goldman Sachs Group dropped their price target on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating on the stock. Weiss Ratings downgraded shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 16th. Finally, Wolfe Research set a $30.00 price target on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies currently has a consensus rating of “Hold” and an average target price of $27.83.

View Our Latest Stock Report on KMTS

Hedge Funds Weigh In On Kestra Medical Technologies

Several large investors have recently modified their holdings of the stock. Farther Finance Advisors LLC bought a new position in Kestra Medical Technologies in the 4th quarter worth about $31,000. Russell Investments Group Ltd. increased its stake in Kestra Medical Technologies by 43.5% during the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Kestra Medical Technologies by 148.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. purchased a new position in Kestra Medical Technologies in the fourth quarter worth about $72,000. Finally, Brown Brothers Harriman & Co. lifted its stake in shares of Kestra Medical Technologies by 26.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock worth $74,000 after buying an additional 656 shares in the last quarter.

About Kestra Medical Technologies

(Get Free Report)

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

Read More

Insider Buying and Selling by Quarter for Kestra Medical Technologies (NASDAQ:KMTS)

Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.